Zacks Research Brokers Lower Earnings Estimates for Hologic

Hologic, Inc. (NASDAQ:HOLX) – Zacks Research cut their Q4 2025 EPS estimates for Hologic in a research note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $1.12 per share for the quarter, down from their previous forecast of $1.13. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s FY2027 earnings at $4.97 EPS.

Several other brokerages also recently issued reports on HOLX. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Wolfe Research assumed coverage on shares of Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Morgan Stanley reduced their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, Evercore ISI reduced their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

Shares of HOLX opened at $61.47 on Monday. Hologic has a 1 year low of $60.34 and a 1 year high of $84.67. The company has a market cap of $13.79 billion, a price-to-earnings ratio of 19.39, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm has a fifty day moving average of $66.06 and a 200-day moving average of $73.94.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%.

Institutional Investors Weigh In On Hologic

A number of institutional investors and hedge funds have recently bought and sold shares of HOLX. FMR LLC lifted its holdings in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. Norges Bank acquired a new stake in Hologic in the 4th quarter valued at about $133,414,000. Boston Partners lifted its holdings in Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the last quarter. Champlain Investment Partners LLC acquired a new stake in Hologic in the 4th quarter valued at about $79,291,000. Finally, Northern Trust Corp lifted its holdings in Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider’s stock valued at $226,898,000 after acquiring an additional 668,086 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.